• . Next generation N-terminal domain androgen receptor inhibitor with improved potency and metabolic stability in castration-resistant poster cancers models. Genitourinary Cancers Symposium 2019. (Abstract# 220).

    Genitouronary Cancers Symposium Poster
  • . Lessons Learned from the metastatic castration-resistant phase 1 of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor. Genitourinary Cancers Symposium 2019. (Abstract# 257).

    Genitouronary Cancers Symposium Poster


  • . Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone. ASCO Annual Meeting 2017(Abstract# 5032).

    ASCO Poster


  • . Targeting the N-terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. The Oncologist 2016

  • . Sintokamide A is a novel antagonist of androgen receptor that uniquely binds activation function-1 in its amino-terminal domain. JBC 2016